Literature DB >> 2404512

Investigation of expression of 5T4 antigen in cervical cancer.

H Jones1, G Roberts, N Hole, I W McDicken, P Stern.   

Abstract

A monoclonal antibody detecting amniotrophoblastic antigen 5T4 has shown reactivity against various neoplastic cell lines and tumour specimens but with a relatively restricted normal tissue expression. This antibody has been investigated as a potential indicator of premalignant changes identified as cervical intra-epithelial neoplasia and malignant cervical lesions using immunohistochemistry on frozen tissue biopsies. The basal cells of normal cervical stratified epithelium exhibited faint staining, but a general increase in intensity and extent of specific labeling of this tissue was seen from the first premalignant stage through to carcinoma. In most cases, this was in accordance with the distribution of dysplastic cells, and was accompanied by increased specific staining of the stromal tissue. All invasive squamous carcinomas of the cervix were 5T4 antigen positive. Common inflammatory non-malignant diseases did show a certain degree of epithelial and stromal reactivity. These results, showing 5T4 reactivity with neoplastic and pre-neoplastic lesions, may provide a quantitative basis for its potential use as a tumour marker in the immunochemical detection on immunoassay of cervical cancer.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2404512      PMCID: PMC1971310          DOI: 10.1038/bjc.1990.21

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

1.  DYSPLASIA OF THE UTERINE CERVIX. INCIDENCE OF REGRESSION, RECURRENCE, AND CANCER.

Authors:  E STERN; P M NEELY
Journal:  Cancer       Date:  1964-04       Impact factor: 6.860

2.  Pathological prognostic indicators in cervical cancer with particular reference to patients under the age of 40 years.

Authors:  C H Buckley; C S Beards; H Fox
Journal:  Br J Obstet Gynaecol       Date:  1988-01

3.  Cervical cancer deaths in young women.

Authors:  L Villard; M Murphy; M P Vessey
Journal:  Lancet       Date:  1989-02-18       Impact factor: 79.321

Review 4.  The role of human papillomaviruses in the pathogenesis and histologic classification of precancerous lesions of the cervix.

Authors:  R J Brescia; A B Jenson; W D Lancaster; R J Kurman
Journal:  Hum Pathol       Date:  1986-06       Impact factor: 3.466

5.  Indium-111 labelled monoclonal antibody to placental alkaline phosphatase in in the detection of neoplasms of testis, ovary, and cervix.

Authors:  A A Epenetos; D Snook; G Hooker; R Begent; H Durbin; R T Oliver; W F Bodmer; J P Lavender
Journal:  Lancet       Date:  1985-08-17       Impact factor: 79.321

6.  Prognostic significance of tissue carcinoembryonic antigen in mild dysplasia of the uterine cervix.

Authors:  J Lindgren; E Vesterinen; E Purola; T Wahlstrom
Journal:  Tumour Biol       Date:  1986

7.  A 72 kD trophoblast glycoprotein defined by a monoclonal antibody.

Authors:  N Hole; P L Stern
Journal:  Br J Cancer       Date:  1988-03       Impact factor: 7.640

8.  Immunohistological distribution of 5T4 antigen in normal and malignant tissues.

Authors:  P J Southall; G M Boxer; K D Bagshawe; N Hole; M Bromley; P L Stern
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

9.  Placental-type alkaline phosphatase in cervical neoplasia.

Authors:  P J McLaughlin; P H Warne; G E Hutchinson; P M Johnson; D F Tucker
Journal:  Br J Cancer       Date:  1987-02       Impact factor: 7.640

10.  Detection of placental-type alkaline phosphatase in ovarian cancer.

Authors:  I W McDicken; P J McLaughlin; P M Tromans; D M Luesley; P M Johnson
Journal:  Br J Cancer       Date:  1985-07       Impact factor: 7.640

View more
  8 in total

1.  Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4.

Authors:  Irina Redchenko; Richard Harrop; Matthew G Ryan; Robert E Hawkins; Miles W Carroll
Journal:  Immunology       Date:  2006-05       Impact factor: 7.397

Review 2.  Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer.

Authors:  Scott S Tykodi; John A Thompson
Journal:  Expert Opin Biol Ther       Date:  2008-12       Impact factor: 4.388

3.  Trophoblast glycoprotein recognised by monoclonal antibody 5T4 maps to human chromosome 6q14-q15.

Authors:  J M Boyle; K H Grzeschik; P R Heath; J E Morten; P L Stern
Journal:  Hum Genet       Date:  1990-04       Impact factor: 4.132

4.  An update on TroVax for the treatment of progressive castration-resistant prostate cancer.

Authors:  Michael Abern; Howard L Kaufman; Kalyan Latchamsetty
Journal:  Onco Targets Ther       Date:  2011-05-24       Impact factor: 4.147

Review 5.  Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin.

Authors:  Tim Eisen; Gunnar Hedlund; Göran Forsberg; Robert Hawkins
Journal:  Curr Oncol Rep       Date:  2014-02       Impact factor: 5.075

6.  Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo.

Authors:  Margherita Passariello; Asami Yoshioka; Kota Takahashi; Shu-Ichi Hashimoto; Toshikazu Inoue; Koji Nakamura; Claudia De Lorenzo
Journal:  J Exp Clin Cancer Res       Date:  2022-09-07

7.  Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4.

Authors:  Rabih Said; Robert J Amato
Journal:  Front Oncol       Date:  2013-07-15       Impact factor: 6.244

8.  The expression of 5T4 antigen in colorectal and gastric carcinoma.

Authors:  T Starzynska; V Rahi; P L Stern
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.